Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy
Takayoshi Tsutamoto, MD*,*,
Atsuyuki Wada, MD*,
Keiko Maeda, MD*,
Naoko Mabuchi, MD*,
Masaru Hayashi, MD*,
Takashi Tsutsui, MD*,
Masato Ohnishi, MD*,
Masanori Fujii, MD*,
Takehiro Matsumoto, MD*,
Takashi Yamamoto, MD*,
Xinwen Wang, MD*,
Shigeru Asai, PhD ,
Tetsuo Tsuji, PhD ,
Hitoshi Tanaka, PhD ,
Yoshihiko Saito, MD ,
Koichiro Kuwahara, MD ,
Kazuwa Nakao, MD and
Masahiko Kinoshita, MD*
* First Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan
Diagnostic Department, Shionogi & Co., Osaka, Japan
Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan

View larger version (19K):
[in a new window]
|
Figure 1 Plasma cardiotrophin-1 (CT-1) concentrations in control subjects and in congestive heart failure (CHF) patients with dilated cardiomyopathy. Mild CHF = New York Heart Association (NYHA) functional class II; severe CHF = NYHA functional class IIIIV. *p < 0.05 versus the value of control subjects; #p < 0.05 versus the value of the mild CHF.
|
|

View larger version (16K):
[in a new window]
|
Figure 2 Plasma cardiotrophin-1 (CT-1) concentrations in patients with dilated cardiomyopathy. Patients were classified into two groups: small left ventricular mass index (LVMI) group and large LVMI, based on the median value of LV mass index. *p < 0.01 versus the value in the small LVMI group.
|
|

View larger version (21K):
[in a new window]
|
Figure 3 Correlation between the plasma cardiotrophin-1 (CT-1) concentrations and the left ventricular (LV) mass index in patients with dilated cardiomyopathy.
|
|
|